Research Progress of CAR-T Cell Immunotherapy in B-Cell Non-Hodgkin's Lymphoma—RReview

VernacularTitle:CAR-T细胞免疫疗法在B细胞非霍奇金淋巴瘤中的应用进展
Author: Mei-Yi WANG ¹ ; Chen TIAN
Author Information

1. 天津医科大学肿瘤医院血液科,国家恶性肿瘤临床医学研究中心,天津市恶性肿瘤临床医学研究中心,天津市肿瘤防治重点实验室,天津 300060
Keywords: B-cell non-Hodgkin's lymphoma; CAR-T; immunotherapy
From: Journal of Experimental Hematology 2024;32(3):970-973
CountryChina
Language:Chinese
Abstract: Chimeric antigen receptor T(CAR-T)cell therapy is a rapidly developing new immunotherapy in recent years.Compared with other therapies,CAR-T has significant advantages for high-risk and relapsed/refractory B cell non-Hodgkin's lymphoma(B-NHL)patients.Currently,a variety of anti-CD19 CAR-T cells have been approved by the FDA for the treatment of B-NHL,such as axicabtagene ciloleucel,tisagenlecucel,lisocababtagene maraleucel and brexucabtagene autoleucel.In addition,many studies are actively exploring and developing different targeted CAR-T cells,which show great potential in B-NHL.This review briefly summarized the latest research progress on the application of CAR-T in common B-NHL.